3 July 2014 in BioMed Research International
Objective. Several studies with contradictory results from different cultures about association of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in schizophrenia and bipolar disorders. Little is known about this association in Arab culture and Egypt. So the present study aimed to assess the association of MTHFR C677T polymorphism in bipolar disorder (BD) and schizophrenia in comparison to control group. The association between MTHFR C677T polymorphism and the age at onset in schizophrenia or BD was also studied.Methods. Polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) were used to examine the genotype and allele frequencies of MTHFR C677T polymorphism in 149 healthy subjects and 134 bipolar and 103 schizophrenia patients.Results. In BD and schizophrenia, there was a higher prevalence of MTHFR C677T polymorphism than healthy subjects. Earlier age at onset was found in patients with BD, carrying one copy of the T allele or CT genotypes but not in patients with schizophrenia.Conclusion. The present findings suggest that the MTHFR C677T polymorphisms are likely to be associated with the risk of developing BD and schizophrenia and influence the age at onset of BD but not the age at onset of schizophrenia.
21 September 2011 in Indian Journal of Hematology and Blood Transfusion
22 February 2015 in Diagnostic Pathology
Cytogenetic analysis has detected an accumulation of genetic lesions in oral cancers. Numerical changes in chromosome 17 might be associated with an up-regulation of p53 gene, and could contribute to critical events in carcinogenesis. The aim of this study was to reveal possible correlations between the numerical aberrations of chromosome 17, deletion or amplification of the P53 gene and histological grading in patients with oral squamous cell carcinoma (OSCC). This study was performed retrospectively on anonymous forty paraffin embedded specimens diagnosed with a primary OSCC. Sections were prepared for p53 immunohistochemical staining and FISH technique evaluation. All studied cases showed a positive nuclear staining with different indices for the p53 protein. Furthermore, statistical analysis showed a significant difference between all histological types of OSCC. In term of P53 immunoreactivity well differentiated OSCC showed the highest, whereas poorly differentiated showed weakest. Regarding chromosome 17 aberrations and p53 gene mutations, Spearman correlation test revealed a statistical significant positive correlation between chromosome 17 abnormalities and p53 gene mutations as well as with the immunohistochemical expression of p53 proteins. Moreover, the positive association between p53 gene mutations and the expression of p53 protein was statistically significant. In the light of the previous findings, we concluded that numerical aberrations of chromosome 17 and p53 gene mutations as well as expression of p53 protein have enormous influence on various cellular processes including differentiation and carcinogenesis. Such knowledge provides an easy and simplified approach to prognosis predilection for OSCC. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2015_232 .
4 July 2017 in Pediatric Hematology and Oncology
This study aimed to determine the prognostic impact of CD200 and CD56 expression in pediatric B cell acute lymphoblastic leukemia (B-ALL) patients, both of which have been implicated in immune tolerance and previously suggested as independent risk factors. CD200 has a central role in immune tolerance that protects stem cells and other critical tissues from immune damage. The expression of CD200/CD56 in leukemic blasts were assessed in leukemic blasts before chemotherapy in 43 bone marrow (BM) and/or peripheral blood (PB) samples by flow cytometry. Twenty eight of 43 B-ALL cases (65%) showed CD200 positive expression, 5 of 43 cases (11.6%) showed CD56 expression, and only 2 patients (4.7%) expressed both CD200 and CD56. Patients with CD200+ and CD56+ were significantly associated with lower platelet count; less tendency for induction of remission response as compared to negative ones (p = .01 for both). The overall survival (OS) and DFS were significantly shorter in CD200+ and CD56+ cases as compared to those with CD200− and CD56− expression. In conclusion, CD200 and/or CD56 positive expression in B-ALL at diagnosis suggest a poor prognosis and may be associated with biological aggressiveness.
16 November 2017 in Comparative Clinical Pathology